Payment overview · 2025
General Payments
$87.54
4 reported records · 4 companies
Healthcare provider profile · identity verified
Gudrun Reed, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKINGS, OR · NPI 1598007437
Verified facts
What the public records show
CMS Open Payments records show Gudrun Reed, M.D. received $87.54 in general payments during 2025 across 4 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.57 | 37.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.43 | 25.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.81 | 21.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.73 | 15.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $87.54 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.57 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 501 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 128 |
| Lisinopril | Lisinopril | 368 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 92 |
| Losartan Potassium | Losartan Potassium | 283 | 83 |
| Gabapentin | Gabapentin | 271 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 255 | 82 |
| Metformin Hcl | Metformin Hcl | 230 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 64 |
| Omeprazole | Omeprazole | 197 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 51 |
| Trazodone Hcl | Trazodone Hcl | 134 | 39 |
| Montelukast Sodium | Montelukast Sodium | 125 | 36 |
| Carvedilol | Carvedilol | 113 | 38 |
| Potassium Chloride | Potassium Chloride | 111 | 42 |
| Furosemide | Furosemide | 110 | 49 |
| Simvastatin | Simvastatin | 105 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 39 |
| Ozempic | Semaglutide | 98 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 28 |
| Ibuprofen | Ibuprofen | 82 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 21 |
| Sertraline Hcl | Sertraline Hcl | 76 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 31 |
| Allopurinol | Allopurinol | 70 | 19 |
| Glimepiride | Glimepiride | 69 | 21 |
| Eliquis | Apixaban | 65 | 22 |
| Warfarin Sodium | Warfarin Sodium | 65 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 15 |
| Glipizide | Glipizide | 59 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 17 |
| Atenolol | Atenolol | 54 | 14 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 18 |
| Baclofen | Baclofen | 48 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 17 |
| Benazepril Hcl | Benazepril Hcl | 47 | 14 |
| Spironolactone | Spironolactone | 47 | 17 |
| Synthroid | Levothyroxine Sodium | 47 | 14 |
| Buspirone Hcl | Buspirone Hcl | 44 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 14 |
| Glipizide Er | Glipizide | 44 | 13 |
| Memantine Hcl | Memantine Hcl | 44 | 13 |
| Tramadol Hcl | Tramadol Hcl | 43 | 12 |
| Propranolol Hcl | Propranolol Hcl | 42 | 18 |
| Chlorthalidone | Chlorthalidone | 41 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Ondansetron Odt | Ondansetron | 38 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 14 |
| Nystatin | Nystatin | 35 | 19 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | 12 |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Alprazolam | Alprazolam | 32 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 11 |
| Finasteride | Finasteride | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $87.54 · 4 records | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE, LEQVIO, OTEZLA, REPATHA, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error